South Korea’s MFDS approves Celltrion’s regdanvimab for COVID-19

Sep 18, 2021

Celltrion announced that South Korea’s MFDS has approved regdanvimab for the extended use in elderly patients aged 50 years and over, or with at least one underlying medical condition with mild symptoms of COVID-19, and in adults patients with moderate symptoms of COVID-19.

Print Page Mail Article